Soliqua Solostar Injection

About

Soliqua Solostar Injection is a fixed-ratio combination of insulin glargine, a long-acting basal insulin, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist. This once-daily injectable medication is indicated for the treatment of adults with type 2 diabetes mellitus who are not adequately controlled on basal insulin or lixisenatide alone. Insulin glargine provides sustained glycemic control by mimicking basal insulin secretion, while lixisenatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. The combination offers comprehensive glycemic management, addressing both fasting and postprandial glucose levels, and often contributes to weight management. By combining two complementary mechanisms of action, Soliqua Solostar helps to achieve better blood sugar control with a potentially lower risk of hypoglycemia compared to higher doses of insulin alone, making it a valuable option in complex diabetes regimens.

Uses

• Management of Type 2 Diabetes Mellitus
• When basal insulin or GLP-1 agonist alone is insufficient
• To improve glycemic control in adults
• As an adjunct to diet and exercise

Directions For Use

Administer as a subcutaneous injection once daily, within one hour before the first meal of the day, as directed by your healthcare provider.

Benefits

• Comprehensive fasting and postprandial glucose control
• Promotes weight loss or is weight neutral
• Convenient once-daily dosing
• Reduces risk of hypoglycemia compared to higher insulin doses alone
• Addresses multiple pathophysiological defects in Type 2 Diabetes
• Improved patient adherence due to combination

Side Effects

• Hypoglycemia (low blood sugar)
• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Injection site reactions
• Headache
• Dizziness
• Fatigue
• Pancreatitis (rare but serious)
• Allergic reactions
• Antibody formation

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can significantly lower blood sugar levels and increase the risk of hypoglycemia.
• Pregnancy - Not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. Insulin is generally preferred.
• Breastfeeding - Avoid during breastfeeding as it is unknown if lixisenatide passes into breast milk and could harm the infant.
• Liver - Use with caution in patients with liver impairment; dose adjustments may be necessary due to altered drug metabolism.
• Kidney - Not recommended for patients with severe kidney impairment (eGFR below a certain threshold) due to the lixisenatide component.
• Lung - No specific contraindications related to lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.